Contact

  • | Estetrol

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

  • Five abstracts on the positive effect of E4 accepted for oral presentation
  • Eleven leading experts to outline why estrogen is critical in contraception and for the treatment of postmenopausal symptoms
  • Data show promising efficacy and safety features of E4, key ingredient in ESTELLE® and DONESTA®

 

Liege, Belgium, 28 November 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, will hold five presentations on the role of estrogens – including its estetrol (E4) – in a symposium at the European Society of Gynaecology Congress, which will take place from 29 November to 02 December in Amsterdam, The Netherlands.

A total of five abstracts will be presented referring to the beneficial effects of the combined oral contraceptive estetrol + drospirenone (E4 + DRSP) on blood pressure, patient-reported outcome measures in postmenopausal women from a phase-3 trial, and a look at E4 as a promising new candidate for menopausal vasomotor symptoms.

E4 is a key active pharmaceutical ingredient in both Mithra’s marketed contraceptive ESTELLE®, and its next generation hormone therapy candidate for postmenopausal symptoms, DONESTA®, with data from preclinical and clinical studies showcasing its promising safety and efficacy profile.

Dr. Graham Dixon, Chief Scientific Officer of Mithra, said, “We are excited that organizers of the ESG congress have taken such an active interest in the positive impact of estetrol. The abstract presentations at the congress will provide these leading experts with a unique opportunity to present the vital role of estrogens in women’s health, and the potential ground-breaking characteristics of our E4 product to support healthcare professionals and women’s confidence in hormone therapy. Current data strongly suggests that E4’s unique molecular mode of action and metabolism contribute notably to its selective pharmacological profile, suggesting its favorable benefit–risk ratio in transforming women’s health. We thank our presenters, who are all leading experts in this field, and we look forward to the many interesting discussions these abstracts will enable us to have at the ESG Congress.”

Mithra’s E4 demonstrates therapeutic efficacy beyond contraception as a component within a combined oral contraceptive with drospirenone and is currently under development for menopausal hormone therapy. It elicits estrogenic activity in uterovaginal tissues, contributing to bone turnover, and shows positive effects on cardiovascular functions. E4’s profile shows a low estrogenic impact on the liver and hemostasis balance, suggesting a diminished thrombotic risk.

 

The following abstracts will be presented at the ESG:

  • Beneficial effects of the combined oral contraceptive estetrol/drospirenone (E4/DRSP) on blood pressure.
    • Authors: J.M. Foidart, Jonathan Douxfils , Mitchell D. Creinin, Kristina Gemzell Danielsson, Ali Kubba and Ulysse Gaspard
    • Saturday, 02 December, 9:45am
    • Speaker: Prof. Kristina Gemzell Danielsson
  • Beneficial effects of the combined oral contraceptive estetrol/drospirenone (E4/DRSP) in participants with high normal baseline blood pressure.
    • Authors: J.M. Foidart, Jonathan Douxfils, Mitchell D. Creinin, Kristina Gemzell Danielsson, Ali Kubba and Ulysse Gaspard
    • Saturday, 02 December. 9:45am
    • Speaker: Prof. Ali Kubba
  • Estetrol (E4):  A Promising New Treatment for the Spectrum of Menopausal Symptoms
    • Authors: Amanda Black, Jean Michel Foidart
    • Friday, 01 December, 15:30
    • Speaker: Prof. Jean-Michel Foidart
  • The Effect of Estetrol (E4) on Patient-Reported Outcome Measures in Postmenopausal Women – Results from a Phase 3 Trial
    • Authors: W.H. Utian, M. Taziaux, A. Black, U. Gaspard, R.A. Lobo and J.M. Foidart
    • Friday, 01 December, 15:30
    • Speaker: Mélanie Taziaux
  • Estetrol (E4), a Promising New Treatment for Menopausal Vasomotor Symptoms: Beneficial Lipid and Carbohydrate Metabolism in a Phase 3 Randomized, Double-blind, Placebo-Controlled Trial
    • Authors: W.H. Utian, M. Taziaux, A. Black, U. Gaspard, R.A. Lobo and J.M. Foidart
    • Friday, 01 December, 15:30
    • Speaker: Prof. Ulysse Gaspard

Download press release

PDF version

Share it

Latest news

View all

Don't miss our news

Get the latest news: subscribe to our newsletter!

Subscribe
Go to Newsroom
Contact

Disclaimer

Please read this carefully as it applies to all persons who visit this website. The following pages contain information relating to an offering and/or admission to trading on a regulated market in relation to securities of Mithra Pharmaceuticals SA ("Mithra Pharmaceuticals"). This information may not be accessed by residents of certain countries based on applicable securities law regulations. Accordingly, if you wish to access this part of the website you must first inform yourself about and then observe the statutory and regulatory requirements applicable to you and to your jurisdiction. In order to establish whether or not you may view the information and documents please read the disclaimer below in full.

THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN ARE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.

This website and the information contained herein or to which it gives access are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the "United States"), Australia, Japan or South Africa, and do not constitute, or form part of, an offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, nor shall there be any sale or purchase of, any securities of Mithra Pharmaceuticals in the United States, Australia, Japan or South Africa or in any other jurisdiction in which such offer, invitation, solicitation, sale, issue, purchase or subscription would be unlawful prior to registration, unless an exemption from registration or qualification under the securities laws of any such jurisdiction is applicable. The securities of Mithra Pharmaceuticals referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act. There will be no public offering of Mithra Pharmaceuticals' securities in the United States.

All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Mithra Pharmaceuticals assumes no responsibility if there is a violation of applicable law and regulations by any person.

No action has been taken by Mithra Pharmaceuticals that would permit an offer of Mithra's securities or the possession or distribution of the materials to which this website gives access or any other offering or publicity material relating to Mithra's securities in any jurisdiction where action for that purpose is required.

Mithra Pharmaceuticals has not authorised any public offering in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area that has implemented Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended from time to time (together with any applicable implementing measures in such Member State, the "Prospectus Regulation"), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Regulation.

In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates, is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Access to electronic versions of these materials is being made available on this webpage by Mithra Pharmaceuticals in good faith and for information purposes only.

By checking the acceptance box below, you confirm and certify that: You are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction, and that you are either: (a) a resident of, and domiciled in, a Member State of the European Economic Area and a qualified investor within the meaning of the Prospectus Regulation, (b) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Regulation and a Relevant Person, or (c) otherwise authorised to access this information pursuant to applicable laws or regulations.

Abort